Baidu
map

Neurology:托吡酯和唑尼沙胺对fMRI认知网络的影响

2017-02-19 xing.T MedSci原创

该研究结果表明,TPM和ZNS与额叶和顶叶认知网络功能异常具有类似的相关性,这是受损的表现相关。TPM也与受损的语言相关失活改善有关。这些研究结果表明对语言和工作记忆网络的功能性神经解剖学存在药物特异性效应。

近日,神经病学领域权威取杂志Neurology上发表了一篇研究文章,研究人员旨在采用fMRI语言任务方法确定托吡酯(TPM)、唑尼沙胺(ZNS)和左乙拉西坦(LEV)对局灶性癫痫患者认知网络激活的效应。

在一项回顾性横断面研究中,研究人员从言语流畅性的fMRI研究的临床数据库中确定了研究的患者,这些患者接受TPM治疗(n=32)或ZNS治疗(n=51)。研究人员匹配了62例服用LEV治疗而不是TPM或ZNS的患者进行临床指标检测。研究人员将抗癫痫联合药物治疗作为干扰变量,并且比较了组间衡量言语流畅性和工作记忆的心理指标。

从扫描仪测量的数据显示相比于LEV和ZNS治疗的患者给予TPM治疗的患者整体表现较差,而且相比于LEC治疗患者,接受ZNS治疗的患者工作记忆表现较差。研究人员发现服用ZNS和TPM患者常见的fMRI效应是减少认知性额叶和顶叶网络激活,相比于服用LEV患者。受损的失活看起来只与TPM治疗有关。

该研究结果表明,TPM和ZNS与额叶和顶叶认知网络功能异常具有类似的相关性,这是受损的表现相关。TPM也与受损的语言相关失活改善有关。这些研究结果表明对语言和工作记忆网络的功能性神经解剖学存在药物特异性效应。

原始出处:

Britta Wandschneider,et al. Effect of topiramate and zonisamide on fMRI cognitive networks. Neurology.   http://dx.doi.org/10.1212/WNL.0000000000003736

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1745977, encodeId=5c331e459778e, content=<a href='/topic/show?id=d8e9e31540c' target=_blank style='color:#2F92EE;'>#知网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73154, encryptionId=d8e9e31540c, topicName=知网)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a88c35641496, createdName=nakerunner, createdTime=Mon Aug 21 19:54:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812870, encodeId=e1fd18128e01a, content=<a href='/topic/show?id=c40e912581e' target=_blank style='color:#2F92EE;'>#认知网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91258, encryptionId=c40e912581e, topicName=认知网络)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Sep 27 16:54:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999835, encodeId=555219998355e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 09 07:54:00 CST 2017, time=2017-07-09, status=1, ipAttribution=)]
    2017-08-21 nakerunner
  2. [GetPortalCommentsPageByObjectIdResponse(id=1745977, encodeId=5c331e459778e, content=<a href='/topic/show?id=d8e9e31540c' target=_blank style='color:#2F92EE;'>#知网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73154, encryptionId=d8e9e31540c, topicName=知网)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a88c35641496, createdName=nakerunner, createdTime=Mon Aug 21 19:54:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812870, encodeId=e1fd18128e01a, content=<a href='/topic/show?id=c40e912581e' target=_blank style='color:#2F92EE;'>#认知网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91258, encryptionId=c40e912581e, topicName=认知网络)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Sep 27 16:54:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999835, encodeId=555219998355e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 09 07:54:00 CST 2017, time=2017-07-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1745977, encodeId=5c331e459778e, content=<a href='/topic/show?id=d8e9e31540c' target=_blank style='color:#2F92EE;'>#知网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73154, encryptionId=d8e9e31540c, topicName=知网)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a88c35641496, createdName=nakerunner, createdTime=Mon Aug 21 19:54:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812870, encodeId=e1fd18128e01a, content=<a href='/topic/show?id=c40e912581e' target=_blank style='color:#2F92EE;'>#认知网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91258, encryptionId=c40e912581e, topicName=认知网络)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Sep 27 16:54:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999835, encodeId=555219998355e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 09 07:54:00 CST 2017, time=2017-07-09, status=1, ipAttribution=)]
    2017-07-09 yinhl1978

相关资讯

NEJM:阿米替林,托吡酯治疗小儿偏头痛无显著疗效

目前还没有药物可以防止小儿偏头痛。

Diabetes Care:苯丁胺与托吡酯缓释剂可有效预防2型糖尿病

随着2型糖尿病患病率逐年上升,患者和社会负担也在逐年加重,当前急需一种能有效防治2型糖尿病的治疗策略。既往研究发现苯丁胺与托吡酯缓释剂(PHEN/TPM ER)联合生活方式干预可显著降低超重/肥胖患者的体重,然而,苯丁胺与托吡酯缓释剂对2型糖尿病进展的影响仍不清楚。 为此,来自美国伯明翰退伍军人医疗中心的Garvey教授及其团队进行了一项研究,在糖尿病前期和代谢综合征患者中,探讨108周苯丁胺与

Baidu
map
Baidu
map
Baidu
map